Division of Cardiac Surgery, Department of Surgery (R.N.P., D.A.D., M.R.C., L.B., J.C.M., A.M.A.), Massachusetts General Hospital and Harvard University, Boston.
Center for Transplantation Sciences (R.N.P., J.A.F., M.R.C., L.B., J.C.M., A.M.A.), Massachusetts General Hospital and Harvard University, Boston.
Circulation. 2020 Oct 6;142(14):1389-1398. doi: 10.1161/CIRCULATIONAHA.120.048186. Epub 2020 Oct 5.
Consistent survival of life-supporting pig heart xenograft recipients beyond 90 days was recently reported using genetically modified pigs and a clinically applicable drug treatment regimen. If this remarkable achievement proves reproducible, published benchmarks for clinical translation of cardiac xenografts appear to be within reach. Key mechanistic insights are summarized here that informed recent pig design and therapeutic choices, which together appear likely to enable early clinical translation.
最近有报道称，使用经过基因改造的猪和一种临床适用的药物治疗方案，可使接受猪心异种移植的患者的生命支持时间超过 90 天。如果这一显著成就能够重现，那么心脏异种移植临床转化的现有基准似乎触手可及。本文总结了一些关键的机制见解，这些见解为最近的猪设计和治疗选择提供了信息，这些选择似乎有可能使异种移植能够早日进入临床。
